1. Single high-dose oral vitamin D3 (stoss) therapy — A solution to vitamin D deficiency in children with cystic fibrosis?
- Author
-
Penny I Field, Tamarah Katz, Adam Jaffe, Yvonne Belessis, John R. Morton, and Darren Shepherd
- Subjects
Pulmonary and Respiratory Medicine ,Male ,medicine.medical_specialty ,Administration, Oral ,Cystic fibrosis ,Gastroenterology ,vitamin D deficiency ,Bone health ,Internal medicine ,Single high dose ,Chart review ,medicine ,Vitamin D and neurology ,Humans ,Pediatrics, Perinatology, and Child Health ,Vitamin D ,Child ,Stoss therapy ,Cholecalciferol ,Retrospective Studies ,business.industry ,Case-control study ,Retrospective cohort study ,medicine.disease ,Vitamin D Deficiency ,Surgery ,Treatment Outcome ,Case-Control Studies ,Pediatrics, Perinatology and Child Health ,Oral vitamin ,Female ,business - Abstract
Objectives To determine the safety and efficacy of stoss therapy on vitamin D levels over a 12month period in children with cystic fibrosis and vitamin D deficiency ( Study design Retrospective chart review of 142 paediatric CF patients from 2007 till 2011. Results Thirty eight children received stoss therapy and 37 children with vitamin D deficiency were not treated and served as a control group. The stoss treated group had a significant and sustained increase in 25-hydroxyvitamin D levels measured at 1, 3, 6 and 12months post treatment compared to controls (94.82±41.0nmol/L, p=0.001; 81.54±24.6nmol/L, p=0.001; 92.18±36.5nmol/L, p=0.008 and 64.6±20.0nmol/L, p=0.006 respectively). At 12months post intervention, the mean difference in vitamin D levels from baseline between the stoss treated group and controls was significant at 15nmol/L compared to 5nmol/L (p=0.038). Conclusion Stoss therapy effectively achieves and maintains levels of 25-hydroxyvitamin D greater than 75nmol/L over 12months.
- Full Text
- View/download PDF